One of the hot areas in oncology new product development is targeted protein degradation (TPD). It offers a lot of clinical and commercial potential, but is scientifically much more complex than inhibitors or antagonists. Perhaps that’s why it’s a topic we enjoy writing about at BSB.

We’re continuing our coverage of the field with a high level view on some of the recent data presented at AACR22 and what to watch out for at ASCO22.

As an added bonus for BSB readers, we have a candid expert interview with Dr Stew Fisher, CSO of C4 Therapeutics, who kindly spoke to BSB about the culmination of several years of research presented at AACR22.

They say the best way to predict the future is to invent it, which is definitely what we expect to happen in the targeted protein degradation space going forward…

To read our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by